• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis assays selected for inclusion in major new ERS-funded study
Share
News

ProAxsis assays selected for inclusion in major new ERS-funded study

September 20, 2018
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that two of its products, the ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial.

The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which 1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome, proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “We’re delighted that this group of eminent researchers in the field of respiratory medicine have chosen to include both the NE immunoassay and NEATstik® in to the protocol of this important study, and look forward to collaborating with many of the top bronchiectasis research groups in Europe.”

Professor James Chalmers, the Chief Investigator of the BRIDGE study, added: “Bronchiectasis is a common disabling and heterogeneous disease that has been neglected in terms of basic and clinical research. This study aims to explore the clinical, microbiological, inflammatory and functional heterogeneity of the disease with the aim of identifying patient endotypes for stratified medicine. We’ve previously demonstrated that active neutrophil elastase can help identify bronchiectasis patients at highest risk of clinical worsening*, so we’re excited about further exploring this and other potential biomarkers in a large, pan-European patient population.”

Any queries concerning ProAxsis’ immunoassay and point-of-care test for measuring active Neutrophil Elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

 

About ProAxsis Limited

ProAxsis is utilising its proprietary ProteaseTag® technology to develop a range of products for the capture, detection and measurement of active protease biomarkers of diseases. The company has already launched activity-based immunoassays for both neutrophil elastase and plasmin, as well as a rapid point-of-care test for neutrophil elastase (NEATstik®). ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University Belfast.

 

About the BRIDGE study

The BRIDGE study – Bronchiectasis Research Involving Databases, Genomics and Endotyping to match the right treatment to the right patient.

 

*Chalmers et al (2017) AJRCCM

September 20, 2018

Related News

Other posts that you should not miss.
Announcements, News

ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19

December 10, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded a high impact …

Read More
December 10, 2020
Posted by David Ribeiro
News

ProAxsis announces new appointments

June 23, 2020
-
Posted by David Ribeiro

ProAxsis Limited, the Belfast-based diagnostics company, is pleased to welcome back Elisha Cain, who re-joins the company …

Read More
June 23, 2020
Posted by David Ribeiro
News, ProteaseTag®

ProAxsis gains further support from Innovate UK

July 24, 2017
-
Posted by Webmaster

Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for …

Read More
July 24, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis to present data on novel immunoassay at 2018 British Thoracic Society Winter Meeting
NEXT POST →
ProAxsis presenting new data at 2018 European Respiratory Society Conference
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis assays selected for inclusion in major new ERS-funded study - ProAxsis